Citations

Clear

9383 citation(s) found for "Thomas, PS".

Analysis of 60 Reported Glioma Risk SNPs Replicates Published GWAS Findings but Fails to Replicate Associations From Published Candidate‐Gene Studies
Walsh, Kyle M. , Anderson, Erik L. , Hansen, Helen M. , Decker, Paul A. , Kosel, Matt, Kollmeyer, Thomas M. , Rice, Terri, Zheng, Shichun, Xiao, Yuanyuan , Chang, Jeffrey S. , McCoy, Lucie , Bracci, Paige M. , Wiemels, Joe, Pico, Alexander R. , Smirnov, Ivan, Sicotte, Hugues , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Wrensch, Margaret , Decker, Paul A. , Kosel, Matthew , Lachance, Daniel Honore , Wiencke, John K. , Kollmeyer, Thomas

Mayo Clinic

Genetic Epidemiology | January 1, 2013 | Volume: 37 | Issue: 2 | Pages: 222-228

10.1002/gepi.21707 | PMID 23280628 Get It

Genomewide association studies (GWAS) and candidate‐gene studies have implicated single‐nucleotide polymorphisms (SNPs) in at least 45 different genes as putative glioma risk factors. Attempts to validate these associations have yielded variable results and few genetic risk factors have been consistently replicated. We conducted a case‐control study of Caucasian glioma cases and controls from the University of California San Francisco (810 cases, 512 controls) and the Mayo Clinic (852 cases, 789 controls) in an attempt to replicate previously reported genetic risk factors for glioma. Sixty SNPs selected from the literature (eight from GWAS and 52 from candidate‐gene studies) were successfully genotyped on an Illumina custom genotyping panel. Eight SNPs in/near seven different genes (TERT, EGFR, CCDC26, CDKN2A, PHLDB1, RTEL1, TP53) were significantly associated with glioma risk in the combined dataset (P < 0.05), with all associations in the same direction as in previous reports. Several SNP associations showed considerable differences across histologic subtype. All eight successfully replicated associations were first identified by GWAS, although none of the putative risk SNPs from candidate‐gene studies was associated in the full case‐control sample (all P values > 0.05). Although several confirmed associations are located near genes long known to be involved in gliomagenesis (e.g., EGFR, CDKN2A, TP53), these associations were first discovered by the GWAS approach and are in noncoding regions. These results highlight that the deficiencies of the candidate‐gene approach lay in selecting both appropriate genes and relevant SNPs within these genes.
Revisiting the Topic of Histochemically Detectable Copper in Various Liver Diseases With Special Focus on Venous Outflow Impairment
Mounajjed, Taofic, Qureshi, Hina, Smyrk, Thomas C. , Oxentenko, Amy S.

Mayo Clinic

American Journal of Clinical Pathology | December 27, 2012 | Volume: 139 | Issue: 1 | Pages: 79-86

10.1309/ajcpdzr4ohdqng3l | PMID 23270902 Get It

A trial of proficiency of nerve conduction: Greater standardization still needed
Dyck, P. James B. , Albers, James W., Wolfe, James, Bolton, Charles F., WALSH, NANCY, Klein, Christopher J. , Zafft, Andrew J., Russell, James W. , Thomas, Karen, Davies, Jenny L., Carter, Rickey E. , Melton, L. Joseph , Litchy, William J. , Klein, Christopher J , Carter, Rickey E

Mayo Clinic

Muscle & Nerve | December 27, 2012 | Volume: 48 | Issue: 3 | Pages: 369-374

10.1002/mus.23765 | PMID 23861198 Get It

ABSTRACTIntroductionThe aim of this study was to test the proficiency (accuracy among evaluators) of measured attributes of nerve conduction (NC).MethodsExpert clinical neurophysiologists, without instruction or consensus development, from 4 different medical centers, independently assessed 8 attributes of NC in 24 patients with diabetes mellitus (DM) on consecutive days.ResultsNo significant intraobserver differences between days 1 and 2 were found, but significant interobserver differences were seen. Use of standard reference values did not correct for these observed differences.ConclusionsInterobserver variability was attributed to differences in performance of NC. It was of sufficient magnitude that it is of concern for the conduct of therapeutic trials. To deal with interrater variability in therapeutic trials, the same electromyographers should perform all NC assessments of individual patients or, preferably, NC procedures should be more standardized. A further trial is needed to test whether such standardization would eliminate interobserver variability. Muscle Nerve 48: 369–374, 2013
Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy
Bosch, Wendelyn , Poowanawittayakom, Nongnooch, Chaikriangkrai, Kongkiat , Mendez, Julio, Hellinger, Walter C. , Gonwa, Thomas A., Krishna, Mani , Pungpapong, Surakit , Pungpapong, Surakit

Mayo Clinic

Transplant Infectious Disease | December 27, 2012 | Volume: 15 | Issue: 1 | Pages: No page available

10.1111/tid.12048 | PMID 23278987 Get It

AbstractMycobacterium tuberculosis infection is one of many opportunistic infections in renal transplant recipients, arising either from reactivation of latent infection or de novo infection, occasionally donor derived. M. tuberculosis hepatitis has never been reported in patients who have received alemtuzumab as part of their renal transplant management. We describe 2 patients who underwent deceased‐donor renal transplantation following alemtuzumab induction therapy and presented with a febrile syndrome, subsequently diagnosed as tuberculous hepatitis, one with disseminated disease. Both responded well to treatment without significant side effects, resulting in excellent graft function. The importance of chemoprophylaxis should be emphasized to minimize the risk of developing active tuberculosis in patients with latent tuberculosis infection undergoing solid organ transplantation.
Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study
Castellano, Daniel , Bajetta, Emilio, Panneerselvam, Ashok, Saletan, Stephen, Kocha, Walter, O’Dorisio, Thomas M. , Anthony, Lowell , Hobday, Timothy J. , Group, RADIANT-2 Study, Group, RADIANT-2 Study

Mayo Clinic

The Oncologist | December 23, 2012 | Volume: 18 | Issue: 1 | Pages: 46-53

10.1634/theoncologist.2012-0263 | PMID 23263288 Get It

AbstractIntroduction.The incidence of colorectal neuroendocrine tumors (NETs) is increasing, and patients with this disease have particularly poor prognoses. Treatment options are limited, and survival times have not improved in the past decade.Methods.A post hoc analysis of the efficacy and tolerability of everolimus plus octreotide long-acting repeatable (LAR) was conducted in patients with colorectal NETs enrolled in the phase III RAD001 in Advanced Neuroendocrine Tumors, Second Trial (RADIANT-2) study. The primary endpoint (progression-free survival [PFS]), secondary endpoints (including objective response rate), and safety were assessed.Results.Patients with colorectal NETs receiving everolimus plus octreotide LAR had a significantly longer median PFS (29.9 months; n = 19) than did those receiving placebo plus octreotide LAR (6.6 months; n = 20). Everolimus plus octreotide LAR treatment also significantly reduced the risk for disease progression (hazard ratio: 0.34; 95% confidence interval: 0.13–0.89; p = .011). Although no objective responses were observed, tumor shrinkage was more frequently noted in the everolimus plus octreotide LAR arm than in the placebo plus octreotide LAR arm (67% vs. 37%, respectively). The combination of everolimus plus octreotide LAR was generally well tolerated by patients with colorectal NETs; rash and stomatitis were the most commonly reported adverse events.Conclusions.Everolimus plus octreotide LAR treatment had significant benefits and improved outcomes for patients with advanced colorectal NETs compared with placebo plus octreotide LAR treatment. Results of this exploratory analysis are consistent with those reported from the RADIANT-2 primary analysis. These findings support additional investigations of everolimus plus octreotide LAR in patients with colorectal NETs.
Evaluation of Fracture Resistance in Aqueous Environment of Four Restorative Systems for Posterior Applications. Part 1
Dhima, Matilda, Assad, Daniel, Volz, John E., An, Kai‐Nan, Berglund, Lawrence J., Carr, Alan B. , Salinas, Thomas

Mayo Clinic

Journal of Prosthodontics | December 22, 2012 | Volume: 22 | Issue: 4 | Pages: 256-260

10.1111/j.1532-849x.2012.00948.x | PMID 23279080 Get It

AbstractPurposeThe goals of this study were to: (1) establish a range of the performance of four restorative systems for posterior single‐tooth crowns under single load to fracture submerged in an aqueous environment, (2) identify restorative system(s) of interest to be examined in the second study phase under sliding contact step‐stress fatigue as full‐contour anatomically appropriate single posterior tooth restoration(s), (3) establish a range for loading/testing for phase 2.Materials and MethodsForty specimens (n = 10/group) of 2 mm uniform thickness were tested. Group 1: monolithic lithium disilicate IPS e.max Press; group 2: IPS e.max ZirPress, 0.8 mm zirconia core with 1.2 mm pressed veneering porcelain; group 3: IPS e.max ZirPress, 0.4 mm zirconia core with 1.6 mm pressed veneering porcelain; group 4: IPS InLine PoM. Specimens were bonded to a block of polycast acrylic resin on a 30° sloped surface with resin cement. Specimens were axially single loaded to failure while submerged under water.ResultsThere was a statistically significant difference (p < 0.001) in failure load among the four restorative systems. Lithium disilicate showed a mean failure load similar to mean maximum posterior bite forces (743.1 ± 114.3 N). IPS e.max Zirpress with a 0.4 mm zirconia core exhibited the lowest mean failure load (371.4 ± 123.0 N).ConclusionFracture resistance of monolithic lithium disilicate in an aqueous environment is promising and requires second phase testing to evaluate the potential of various thicknesses appropriate for posterior single tooth applications. Doubling the IPS e.max Zirpress zirconia core from 0.4 mm to 0.8 mm increased the fracture resistance of this restorative system threefold.
Use of Compliance Measures in an Analysis of the Effect of Diltiazem on Mortality and Reinfarction After Myocardial Infarction
Oakes, David , Moss, A.J., Fleiss, Joseph L., Bigger, J. Thomas, Therneau, TM, Eberly, Shirley , Manatunga, Amita K. , Carleen, Eric, Benhorin, Jesaia, Post-Infa, The Multicenter Diltiazem, McDermott, Michael P. , McDermott, Michael

Mayo Clinic

Journal of the American Statistical Association | December 20, 2012 | Volume: 88 | Issue: 421 | Pages: 44-49

10.1080/01621459.1993.10594287 Get It

Tumor Escape and Progression under Immune Pressure
Egilmez, Nejat K. , Knutson, Keith L. , Selvan, Senthamil R. , Ostberg, Julie R. , Manjili, Masoud H. , Knutson, Keith L.

Mayo Clinic

Clinical and Developmental Immunology | December 19, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-2

10.1155/2012/641079 | PMID 23316254 Get It

Lymphangioleiomyomatosis: Calling It What It Is: A Low-Grade, Destructive, Metastasizing Neoplasm
McCormack, Francis X. , Colby, Thomas V. , Moss, Joel , Travis, William D. , Henske, Elizabeth P. , McCormack, Francis X

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | December 17, 2012 | Volume: 186 | Issue: 12 | Pages: 1210-1212

10.1164/rccm.201205-0848oe | PMID 23250499 Get It

Improvement in Student Science Proficiency Through InSciEd Out
Pierret, Chris , Sonju, James D., Leicester, Jean E., Hoody, Maggie, LaBounty, Thomas J., Frimannsdottir, Katrin R., Ekker, Stephen C. , Ekker, Stephen C

Mayo Clinic

Zebrafish | December 17, 2012 | Volume: 9 | Issue: 4 | Pages: 155-168

10.1089/zeb.2012.0818 | PMID 23244687 Get It

Abstract Integrated Science Education Outreach (InSciEd Out) is a collaboration formed between Mayo Clinic, Winona State University, and Rochester Public Schools (MN) with the shared vision of achieving excellence in science education. InSciEd Out employs an equitable partnership model between scientists, teachers, education researchers, and the community. Teams of teachers from all disciplines within a single school experience cutting-edge science using the zebrafish model system, as well as current pedagogical methods, during a summer internship at the Mayo Clinic. Within the internship, the teachers produce new curriculum that directly addresses opportunities for science education improvement at their own school. Zebrafish are introduced within the new curriculum to support a living model of the practice of science. Following partnership with the InSciEd Out program and 2 years of implementation in the classroom, teacher-interns from a K–8 public school reported access to local scientific technology and expertise they had not previously recognized. Teachers also reported improved integration of other disciplines into the scientific curriculum and a flow of concepts vertically from K through 8. Students more than doubled selection of an Honors science track in high school to nearly 90%. 98% of students who took the Minnesota Comprehensive Assessments in their 5 th and 8 th grade year (a span that includes 2 years of InSciEd Out) showed medium or high growth in science proficiency. These metrics indicate that cooperation between educators and scientists can result in positive change in student science proficiency and demonstrate that a higher expectation in science education can be achieved in US public schools.